Away from the drama surrounding supply of its COVID-19 vaccine to the EU, AstraZeneca PLCis reaping the first rewards of a 2019 collaboration in artificial intelligence with computational medicines specialist firm BenevolentAI Limited, with the selection of a novel chronic kidney disease (CKD) target to advance into drug development. This will be the first AI-generated target from the collaboration to enter the company’s research portfolio.
The big pharma firm recruited BenevolentAI as part of an initiative to secure future growth using technologies like machine learning...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?